BIODESIX, INC. Operating Expenses
BIODESIX, INC. (BDSX) reported Operating Expenses of $32.25 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-05
- BIODESIX, INC. operating expenses for the quarter ending 2026-06-30 was $32.25M, a 8.45% increase year-over-year.
- BIODESIX, INC. operating expenses for the quarter ending 2026-03-31 was $31.76M, a 17.21% increase year-over-year.
- BIODESIX, INC. operating expenses for the quarter ending 2025-12-31 was $30.72M, a 13.46% increase year-over-year.
- BIODESIX, INC. operating expenses for the quarter ending 2025-09-30 was $28.82M, a 7.77% increase year-over-year.
- BIODESIX, INC. operating expenses for fiscal 2025 was $116.37M, a 9.97% increase from fiscal 2024.
- BIODESIX, INC. operating expenses for fiscal 2024 was $105.82M, a 17.02% increase from fiscal 2023.
- BIODESIX, INC. operating expenses for fiscal 2023 was $90.43M, a 1.84% increase from fiscal 2022.
- BIODESIX, INC. operating expenses for fiscal 2022 was $88.80M, a 6.96% decline from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $32.25M 10-Q · filed 2026-08-05 | $64.00M 10-Q · filed 2026-08-05 | $94.73M derived: sum of 3 quarters · filed 2026-08-05 | $123.55M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $31.76M 10-Q · filed 2026-05-04 | $62.48M derived: sum of 2 quarters · filed 2026-05-04 | $91.30M derived: sum of 3 quarters · filed 2026-05-04 | $121.03M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $30.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $59.54M derived: sum of 2 quarters · filed 2026-02-26 | $89.28M derived: sum of 3 quarters · filed 2026-08-05 | $116.37M 10-K · filed 2026-02-26 |
| 2025-09-30 | $28.82M 10-Q · filed 2025-11-03 | $58.56M derived: sum of 2 quarters · filed 2026-08-05 | $85.65M 10-Q · filed 2025-11-03 | $112.73M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $29.74M 10-Q · filed 2026-08-05 | $56.83M 10-Q · filed 2026-08-05 | $83.91M derived: sum of 3 quarters · filed 2026-08-05 | $110.65M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $27.09M 10-Q · filed 2026-05-04 | $54.17M derived: sum of 2 quarters · filed 2026-05-04 | $80.91M derived: sum of 3 quarters · filed 2026-05-04 | $107.08M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $27.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $53.82M derived: sum of 2 quarters · filed 2026-02-26 | $79.98M derived: sum of 3 quarters · filed 2026-02-26 | $105.82M 10-K · filed 2026-02-26 |
| 2024-09-30 | $26.74M 10-Q · filed 2025-11-03 | $52.90M derived: sum of 2 quarters · filed 2025-11-03 | $78.74M 10-Q · filed 2025-11-03 | $100.28M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $26.16M 10-Q · filed 2025-08-07 | $52.00M 10-Q · filed 2025-08-07 | $73.54M derived: sum of 3 quarters · filed 2025-08-07 | $94.20M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $25.84M 10-Q · filed 2025-05-13 | $47.38M derived: sum of 2 quarters · filed 2025-05-13 | $68.04M derived: sum of 3 quarters · filed 2025-05-13 | $90.84M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $21.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $42.20M derived: sum of 2 quarters · filed 2025-03-03 | $65.00M derived: sum of 3 quarters · filed 2025-03-03 | $90.43M 10-K · filed 2025-03-03 |
| 2023-09-30 | $20.66M 10-Q · filed 2024-11-01 | $43.46M derived: sum of 2 quarters · filed 2024-11-01 | $68.89M 10-Q · filed 2024-11-01 | $92.39M derived: sum of 4 quarters · filed 2024-11-01 |
| 2023-06-30 | $22.80M 10-Q · filed 2024-08-07 | $48.23M 10-Q · filed 2024-08-07 | $71.72M derived: sum of 3 quarters · filed 2024-08-07 | $93.44M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $25.43M 10-Q · filed 2024-05-08 | $48.93M derived: sum of 2 quarters · filed 2024-05-08 | $70.64M derived: sum of 3 quarters · filed 2024-05-08 | $93.22M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $23.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $45.21M derived: sum of 2 quarters · filed 2024-03-01 | $67.79M derived: sum of 3 quarters · filed 2024-03-01 | $88.80M 10-K · filed 2024-03-01 |
| 2022-09-30 | $21.72M 10-Q · filed 2023-11-07 | $44.29M derived: sum of 2 quarters · filed 2023-11-07 | $65.30M 10-Q · filed 2023-11-07 | $84.20M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $22.58M 10-Q · filed 2023-08-07 | $43.59M 10-Q · filed 2023-08-07 | $62.49M derived: sum of 3 quarters · filed 2023-08-07 | $82.11M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $21.01M 10-Q · filed 2023-05-11 | $39.91M derived: sum of 2 quarters · filed 2023-05-11 | $59.53M derived: sum of 3 quarters · filed 2023-05-11 | $82.01M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $18.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $38.52M derived: sum of 2 quarters · filed 2023-03-06 | $61.00M derived: sum of 3 quarters · filed 2023-03-06 | $95.45M 10-K · filed 2023-03-06 |
| 2021-09-30 | $19.62M 10-Q · filed 2022-11-03 | $42.09M derived: sum of 2 quarters · filed 2022-11-03 | $76.54M 10-Q · filed 2022-11-03 | $106.22M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $22.47M 10-Q · filed 2022-08-04 | $56.92M 10-Q · filed 2022-08-04 | $86.60M derived: sum of 3 quarters · filed 2022-08-04 | $102.04M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $34.45M 10-Q · filed 2022-05-11 | $64.13M derived: sum of 2 quarters · filed 2022-05-11 | $79.56M derived: sum of 3 quarters · filed 2022-05-11 | $89.42M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $29.68M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $45.12M derived: sum of 2 quarters · filed 2022-03-14 | $54.97M derived: sum of 3 quarters · filed 2022-03-14 | $68.49M 10-K · filed 2022-03-14 |
| 2020-09-30 | $15.43M 10-Q · filed 2021-11-15 | $25.29M derived: sum of 2 quarters · filed 2021-11-15 | $38.81M 10-Q · filed 2021-11-15 | $50.62M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $9.86M 10-Q · filed 2021-08-10 | $23.38M 10-Q · filed 2021-08-10 | $35.19M derived: sum of 3 quarters · filed 2021-08-10 | $48.16M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $13.52M 10-Q · filed 2021-05-11 | $25.33M derived: sum of 2 quarters · filed 2021-05-11 | $38.30M derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | $11.81M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $24.79M derived: sum of 2 quarters · filed 2021-03-16 | $51.29M 10-K · filed 2021-03-16 | |
| 2019-09-30 | $12.97M 10-Q · filed 2020-12-10 | $39.48M 10-Q · filed 2020-12-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |